The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1484934
This article is part of the Research Topic Novel Pharmacological Targets and Strategies to treat Neglected Global Diseases (NGDs): An LMIC Perspective View all 5 articles
Impact on parasitemia, survival time and pro-inflammatory immune response in mice infected with Plasmodium berghei treated with Eleutherine plicata
Provisionally accepted- 1 Federal University of Pará, Belém, Brazil
- 2 Evandro Chagas Institute, Ananindeua, Brazil
In vitro studies with Plasmodium falciparum have demonstrated the antiparasitic activity of Eleutherine plicata, attributed to its naphthoquinones. This study reports on pro-inflammatory changes in mice infected with Plasmodium berghei and correlates these changes with parasitemia and survival. The ethanol extract of E. plicata (EEEp) was fractionated under reflux to obtain the dichloromethane fraction (FDMEp) and isolated compounds from E. plicata, relating these to survival time and parasitemia. Antimalarial activity was evaluated using the Peters suppressive test, with mice infected with P. berghei and treated with E. plicata, assessing parasitemia and survival over 30 days. The proinflammatory profile was determined by measuring cytokines and nitric oxide levels. EEEp, FDMEp, and eleutherol showed activity on the 5th day of infection, with only FDMEp being active on the 8th day. Treatment with EEEp and FDMEp extended animal survival, reduced IFN-γ and NO levels, and increased IL-10 levels. Eleutherol significantly altered the response, with eleutherol glucuronide seemingly active by binding to lactate dehydrogenase, inhibiting hemozoin metabolism, leading to parasite death. Pro-inflammatory changes did not appear to correlate with survival and reduced parasitemia. In summary, FDMEp and eleutherol reduced parasitemia, extended survival, and modulated the inflammatory response. FDMEp and eleutherol are promising candidates for developing new antimalarial drugs.
Keywords: Eleutherol, eleutherol glucuronide, isoeleutherin, Eleutherin, Malaria
Received: 22 Aug 2024; Accepted: 12 Nov 2024.
Copyright: © 2024 Quadros Gomes, Castro, Ferreira, Patrick Cordovil Brigido, Varela, Vale, Carneiro, Dolabela and Percario. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Maria Fani Dolabela, Federal University of Pará, Belém, Brazil
Sandro Percario, Federal University of Pará, Belém, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.